Caffeine as a Therapy for Parkinson's Disease
Caffeine as a Therapeutic Agent in Parkinson's Disease
Sponsor: McGill University Health Centre/Research Institute of the McGill University Health Centre
Listed as NCT01738178, this PHASE3 trial focuses on Parkinson's Disease and remains completed. Sponsored by McGill University Health Centre/Research Institute of the McGill University Health Centre, it has been updated 8 times since 2014, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE3
-
Oct 2019 — Jan 2021 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Oct 2019 [monthly]
Completed PHASE3
-
Apr 2017 — Jun 2018 [monthly]
Completed PHASE3
Status: Active Not Recruiting → Completed
-
Jan 2017 — Apr 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Apr 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- McGill University Health Centre/Research Institute of the McGill University Health Centre
- Movement Disorder Clinic - Deer Lodge Centre
- Pontifícia Universidade Católica do Paraná
- The Ottawa Hospital
- UBC Hospital
- University Health Network, Toronto
- University of Calgary
- University of Newfoundland and Eastern Health
For direct contact, visit the study record on ClinicalTrials.gov .